Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
1. A therapeutic preparation comprising parathyroid hormone (PTH), the preparation shaped as a solid tissue penetrating member and configured to penetrate and be inserted into an intestinal wall after oral ingestion, wherein upon insertion, the preparation releases PTH into the blood stream from the intestinal wall by degradation of the tissue penetrating member,
wherein the tissue penetrating member has sufficient stiffness to be advanced completely into the intestinal wall by the application of a force to the tissue penetrating member,
wherein a dose of PTH in the preparation is in a range from about 10 to 30 μg,
wherein the preparation is adapted to be orally delivered in a swallowable capsule, and
wherein the preparation is adapted to be operably coupled to delivery means having a first configuration and a second configuration, the preparation being contained within the capsule in the first configuration and advanced out of the capsule and into the intestinal wall in the second configuration.
2. The preparation of claim 1 , wherein all of the preparation is in solid form.
3. The preparation of claim 1 , wherein the delivery means comprises a least one expandable balloon having an expanded and a non-expanded state and the first configuration is the non-expanded state and the second configuration is the expanded state.
4. The preparation of claim 1 , wherein the preparation comprises a biodegradable material which degrades within the intestinal wall to release PTH into the blood stream.
5. The preparation of claim 4 , wherein the biodegradable material comprises polylactic-co-glycolic acid (PLGA), a sugar or maltose.
6. The preparation of claim 1 , wherein the preparation comprises at least one pharmaceutical excipient.
7. The preparation of claim 6 , wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant.
8. The preparation of claim 7 , wherein the binder comprises polyethylene glycol (PEG).
9. The preparation of claim 1 , wherein the tissue penetrating member comprises a biodegradable material which degrades within the intestinal wall to release PTH into the blood stream.
10. The preparation of claim 9 , wherein the biodegradable material comprises maltose or PLGA.
11. The preparation of claim 1 , wherein a weight percent of PTH or in the tissue penetrating member comprises between about 1 to 2%.
12. The preparation of claim 1 , wherein the tissue penetrating member includes a retaining feature for retaining the tissue penetrating member within the intestinal wall after insertion.
13. The preparation of claim 12 , wherein the retaining feature comprises at least one of a barb or an inverse taper shape of the tissue penetrating member.
14. The preparation of claim 1 , wherein the PTH is contained in the tissue penetrating member in a shaped section.
15. The preparation of claim 14 , wherein the shaped section has a cylinder or pellet shape.
16. The preparation of claim 1 , wherein the preparation is configured to produce a long-term release of PTH.
17. The preparation of claim 16 , wherein the long-term release of PTH is about 12 hours.